NCT02464670View on ClinicalTrials.gov

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

May 24, 2018

Study Completion Date

May 24, 2018

Conditions
Ebola Vaccine
Interventions
BIOLOGICAL

INO-4201

INO-4201 delivered IM followed by Electroporation

BIOLOGICAL

INO-4202

INO-4202 delivered IM followed by Electroporation

BIOLOGICAL

INO-4201

INO-4201 delivered ID followed by Electroporation

BIOLOGICAL

INO-4212

INO-4212 delivered IM followed by Electroporation

BIOLOGICAL

INO-4212 + INO-9012

INO-4212 + INO-9012 delivered IM followed by Electroporation

BIOLOGICAL

INO-4201 + INO-9012

INO-4201 + INO-9012 delivered ID followed by Electroporation

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

33143

QPS MRA, Miami

64114

The Center for Pharmaceutical Research, Kansas City

Sponsors
All Listed Sponsors
collaborator

GeneOne Life Science, Inc.

INDUSTRY

collaborator

Defense Advanced Research Projects Agency

FED

lead

Inovio Pharmaceuticals

INDUSTRY

NCT02464670 - Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers | Biotech Hunter | Biotech Hunter